Acquisition / mergerFiled on BSE ·
Fredun Pharmaceuticals acquires 26% stake in Goodman Vetcare Pvt. Ltd. in 2026
Fredun Pharma · Pharmaceuticals & Biotechnology
What the filing says
- Fredun Pharmaceuticals Limited acquired a 26% stake in Goodman Vetcare Pvt. Ltd., valuing the company at ₹300 crore.
- Goodman Vetcare operates 3 stores in Mumbai/Navi Mumbai and targets expansion to at least 8 new stores by FY31, aiming ₹100 crore revenue.
- Fredun Pharmaceuticals reported FY26 revenues of ₹639.12 crore, EBITDA of ₹94.79 crore, and PAT of ₹33.21 crore.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Fredun Pharma
Other acquisition / merger filings this fortnight
- Acquisition / mergerMeghmani Organi.Meghmani Organics Limited announces NCLT sanction of merger with subsidiaries
- Acquisition / mergerShakti PumpsShakti Pumps invests ₹10 crore in wholly owned subsidiary Shakti Energy Solutions
- Acquisition / mergerElevate Campuses LtdElevate Campuses Limited subscribes to Class A OCRPS in Elevate UAE for ₹601 crore
- Acquisition / mergerLloyds MetalsLloyds Metals and Energy credits 3.5 crore shares of Thriveni Earthmovers
- Acquisition / mergerTata Consultancy Services LtdTata Consultancy Services Ltd reports Q2 and H1 FY 2026-27 results, declares interim dividend
- Acquisition / mergerTata Consultancy Services LtdTata Consultancy Services reports Q2 & H1 FY 2026-27 results, declares interim dividend
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.